Three bidders in race for Serbia’s Galenika

By bne IntelliNews July 28, 2016

India’s Cadilapharm, Brazil’s EMS S.A. and a consortium of Russia’s LLC NPA and Frontier from Great Britain, have submitted bids for the acquisition of a 25% stake in Serbia’s state-controlled pharmaceutical giant Galenika, the ministry of economy announced on July 27, when the deadline for submission of letters of interest for the acquisition expired.

The acquisition of a quarter of the company is important for its further operations as currently its financial debts amount to $220mn and it still employs 1,400 people. The economy ministry initially launched the tender on April 4, setting the starting price at just €7mn. The deadline has since been extended twice.

The ministry said bids will be opened on July 29 at the ministry’s building. Initially only envelopes with information about the bidders will be opened, while the duration of the analysing process will depend on the quality of the submitted documentation. Afterwards, the ministry will open financial bids.

The bidder that proposes employment for the largest number of workers will have advantage. The amount the bidders offer for the 25% stake will also be important.The final list as well as the best bidder will be announced by the government. Negotiations with the top bidders can last a maximum of 90 days.

Daily Blic reported on July 25 that Serbia’s government plans to write off €130mn Galenika's debt if the sale of the 25% stake in the company fails.

Besides huge financial debts which amounted to $220mn, Galenika struggled under allegedly corrupt management for years. Efforts to tackle this problem finally started in April 2014 when Serbian police arrested several of Galenika's former managers, accusing them of abuse of office and siphoning off money from the company. Most were members of the Socialist Party of Serbia (SPS), which has been a minority coalition partner or supporter of all Serbian governments since 2004. Both the tax authorities and the police brought charges against the former managers, alleging they caused some €75mn damage to Galenika, which benefitted local drug trader Velefarm. The process is still ongoing.

The government currently owns 70% of the company, while 15% belongs to the Equity Fund and the remaining 15% to other shareholders.

Galenika once had a market share of 60% in the former Yugoslavian markets of 24mn people. Nowadays, it controls only around 10% of the Serbian market of 7.1mn people.

Related Articles

RBI doubles net profit y/y in Q1 as Russian business recovers

Raiffeisen Bank International (RBI), the second largest bank operating across Central and Eastern Europe by assets, reported that net profit almost doubled year-on-year to €220mn in the first ... more

China's Hesteel Group to boost investments in Serbia’s Smederevo steel mill

Representatives of China's Hesteel Group, which acquired Serbia’s only steel mill Zelezara Smederevo in July 2016, plan to invest ... more

French court refuses to extradite ex-Kosovo PM Haradinaj to Serbia

The Court of Appeals in the French town of Colmar decided on April 27 not to extradite Kosovo’s former Prime Minister Ramush Haradinaj to Serbia.  The decision was celebrated in Kosovo and ... more

Register here to continue reading this article and 2 more for free or purchase 12 months full website access including the bne Magazine for just $119/year.

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

Thank you. Please complete your registration by confirming your email address.
A confirmation email has been sent to the email address you provided.

To continue viewing our content you need to complete the registration process.

Please look for an email that was sent to with the subject line "Confirmation bne IntelliNews access". This email will have instructions on how to complete registration process. Please check in your "Junk" folder in case this communication was misdirected in your email system.

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

If you have any questions please contact us at sales@intellinews.com

Subscribe to bne IntelliNews website and magazine

Subscribe to bne IntelliNews website and monthly magazine, the leading source of business, economic and financial news and commentary in emerging markets.

Your subscription includes:
  • Full access to the bne content daily news and features on the website
  • Newsletters direct to your mailbox
  • Print and digital subscription to the monthly bne magazine
  • Digital subscription to the weekly bne newspaper

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

bne IntelliNews
$119 per year

All prices are in US dollars net of applicable taxes.

If you have any questions please contact us at sales@intellinews.com

Register for free to read bne IntelliNews Magazine. You'll receive a free digital subscription.

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

Thank you. Please complete your registration by confirming your email address.
A confirmation email has been sent to the email address you provided.

IntelliNews Pro offers daily news updates delivered to your inbox and in-depth data reports.
Get the emerging markets newswire that financial professionals trust.

"No day starts for my team without IntelliNews Pro" — UBS

Thank-you for requesting an IntelliNews Pro trial. Our team will be in contact with you shortly.

Dismiss